Company intelligence / Profile preview

SecureBio

Cambridge, Massachusetts, USAsecurebio.org ↗

Ownership: Private
Development stage: Other

Overview

SecureBio is a nonprofit focused on developing new technologies and policy proposals to delay, detect, and defend against catastrophic pandemics. Its main projects include early warning systems for novel pathogens via metagenomic sequencing (Nucleic Acid Observatory), AI risk assessment tools at the intersection of artificial intelligence and biotechnology misuse, advocacy for pandemic-proof PPE, far-UVC indoor air disinfection research, and DNA synthesis screening software through its SecureDNA initiative.

Therapeutic areas: Infectious Diseases
Industry: Academic Hospital/University/Research

Beyond the preview

Go deeper on SecureBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SecureBio.

Explore the full profile